gliclazide has been researched along with Alloxan Diabetes in 97 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of insulin and gliclazide therapy on endoplasmic reticulum (ER) stress and insulin sensitivity in the liver of type 2 diabetic rats." | 7.78 | [The effects of insulin and gliclazide therapy on endoplasmic reticulum stress and insulin sensitivity in liver of type 2 diabetic rats]. ( Bi, Y; Cai, MY; Chen, X; Liang, H; Liao, LZ; Sun, WP; Weng, JP; Zhu, YH, 2012) |
| "The present study was hypothesized to investigate the hepatoprotective nature of resveratrol in averting hyperglycemia-mediated oxidative stress by measuring extent of oxidant stress and levels of proinflammatory cytokines and antioxidant competence in the hepatic tissues of streptozotocin-nicotinamide-induced diabetic rats." | 7.76 | Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats. ( Palsamy, P; Sivakumar, S; Subramanian, S, 2010) |
| "Hyperglycemia influences ischemia-induced [Ca2+]i dynamics predominantly in the intermediate layers of the retina, and gliclazide, as compared to glibenclamide without a free radical scavenging activity, potently attenuates the ischemia-induced changes in the calcium dynamics." | 7.73 | Gliclazide attenuates the intracellular Ca2+ changes induced in vitro by ischemia in the retinal slices of rats with streptozotocin-induced diabetes. ( Harata, N; Kinukawa, J; Shimura, M; Tamai, M, 2005) |
| "This suggests that gliclazide could directly improve abnormalities in the retinal microcirculation independent of blood glucose control and possibly have selective therapeutic benefits in preventing early, critical events in diabetic retinopathy compared with other sulphonylurea drugs." | 7.71 | Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide. ( Inoda, S; Itou, Y; Kakehashi, A; Kanazawa, Y; Kawakami, M; Kinoshita, N; Kuroki, M; Yasu, T, 2002) |
| "The body weight increased after the treatment in the normal group,blank group,and gliclazide group [(241." | 3.81 | [Alisma versus Gliclazide in the Treatment of Primary Diabetes in Goto-Kakizaki Rats]. ( Ding, CY; Shi, NC; Tan, QY, 2015) |
| "To investigate the effect of insulin and gliclazide therapy on endoplasmic reticulum (ER) stress and insulin sensitivity in the liver of type 2 diabetic rats." | 3.78 | [The effects of insulin and gliclazide therapy on endoplasmic reticulum stress and insulin sensitivity in liver of type 2 diabetic rats]. ( Bi, Y; Cai, MY; Chen, X; Liang, H; Liao, LZ; Sun, WP; Weng, JP; Zhu, YH, 2012) |
| "The present study was hypothesized to investigate the hepatoprotective nature of resveratrol in averting hyperglycemia-mediated oxidative stress by measuring extent of oxidant stress and levels of proinflammatory cytokines and antioxidant competence in the hepatic tissues of streptozotocin-nicotinamide-induced diabetic rats." | 3.76 | Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats. ( Palsamy, P; Sivakumar, S; Subramanian, S, 2010) |
| "Hyperglycemia influences ischemia-induced [Ca2+]i dynamics predominantly in the intermediate layers of the retina, and gliclazide, as compared to glibenclamide without a free radical scavenging activity, potently attenuates the ischemia-induced changes in the calcium dynamics." | 3.73 | Gliclazide attenuates the intracellular Ca2+ changes induced in vitro by ischemia in the retinal slices of rats with streptozotocin-induced diabetes. ( Harata, N; Kinukawa, J; Shimura, M; Tamai, M, 2005) |
| "The combined treatment of deprenyl and gliclazide may contribute to the control of the physiopathological mechanisms underlying both the process of aging and type 2 diabetes by reducing oxidant stress and DNA damage, improving antioxidant status, and increasing survival, and may have implications for further clinical studies." | 3.73 | Effect of I-deprenyl and gliclazide on oxidant stress/antioxidant status and dna damage in a diabetic rat model. ( Alper, G; Caglayan, O; Duman, E; Irer, S; Yilmaz, C, 2005) |
| "This suggests that gliclazide could directly improve abnormalities in the retinal microcirculation independent of blood glucose control and possibly have selective therapeutic benefits in preventing early, critical events in diabetic retinopathy compared with other sulphonylurea drugs." | 3.71 | Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide. ( Inoda, S; Itou, Y; Kakehashi, A; Kanazawa, Y; Kawakami, M; Kinoshita, N; Kuroki, M; Yasu, T, 2002) |
| " Diabetic vascular complications arise from increased vascular endothelial inflammation and oxidative stress as well as decreased nitric oxide bioavailability in the vessel walls due to poor glycemic control." | 1.62 | Combination of Captopril with Gliclazide Decreases Vascular and Renal Complications and Improves Glycemic Control in Rats with Streptozotocin- Induced Diabetes Mellitus. ( Abo-Saif, AA; Kozman, MR; Messiha, BAS; Mizar, SMM, 2021) |
| "Treatment with gliclazide alone decreased serum glucose, total cholesterol, triglycerides, malondialdehyde, tumor necrosis factor-alpha and nuclear factor kappa-Beta while increased serum C-peptide, superoxide dismutase, reduced glutathione and adiponectin levels." | 1.56 | New combination therapy of gliclazide and quercetin for protection against STZ-induced diabetic rats. ( Abdelkader, NF; Badawi, MA; Eitah, HE; Gamaleldin, AA; Kenawy, SA; Maklad, YA, 2020) |
| "Solid lipid nanoparticles (SLNs) are considered a promising system in enhancing the oral bioavailability of poorly water-soluble drugs; owing to their intrinsic ability to increase the solubility together with protecting the incorporated drugs from extensive metabolism." | 1.56 | Lipid-Based Gliclazide Nanoparticles for Treatment of Diabetes: Formulation, Pharmacokinetics, Pharmacodynamics and Subacute Toxicity Study. ( El-Kamel, AH; Hassaan, PS; Khalifa, HM; Nazief, AM; Sokar, MS, 2020) |
| " Based on experimental data, the combination index of the hypoglycemic drugs like metformin and gliclazide in combination with different doses of mangiferin was determined using COMPUSYN software." | 1.51 | Antidiabetic effect of mangiferin in combination with oral hypoglycemic agents metformin and gliclazide. ( Malarvizhi, R; Mani, S; Nithya, P; Sekar, V; Vasanthi, HR, 2019) |
| " The solubility, dissolution rate and bioavailability of gliclazide SGNCs were significantly improved compared to pure gliclazide." | 1.51 | Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model. ( Bhattamisra, SK; Krishnamoorthy, R; Panda, BP; Patnaik, S; Seng, LB; Shivashekaregowda, NKH, 2019) |
| "Gliclazide treatment lessens diabetic nephropathy, probably partially by suppressing the GRP78- and sXBP1-mediated ER response." | 1.48 | Involvement of glucose-regulated protein 78 and spliced X-box binding protein 1 in the protective effect of gliclazide in diabetic nephropathy. ( Ren, X; Wang, X; Zhang, M; Zhang, YW, 2018) |
| "Gliclazide is a drug commonly used in type 2 diabetes mellitus." | 1.46 | High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect. ( Al-Salami, H; Calasan, J; Golocorbin-Kon, S; Lalic-Popovic, M; Mikov, M; Milijasevic, B; Vukmirovic, S, 2017) |
| "Since chronic kidney disease due to diabetic nephropathy (DN) is becoming an ever larger health burden worldwide, more effective therapies are desperately needed." | 1.43 | Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats. ( Ahmed, LA; El-Latif, HA; Hassanein, NM; Mahfoz, AM; Shoka, AA, 2016) |
| "Gliclazide (G) is a commonly prescribed drug for Type 2 diabetes (T2D)." | 1.43 | A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes. ( Al-Salami, H; Arfuso, F; Chen-Tan, N; Mathavan, S, 2016) |
| "Drug Gliclazide (Glz) has limited solubility and low bioavailability." | 1.42 | Controlled release of anti-diabetic drug Gliclazide from poly(caprolactone)/poly(acrylic acid) hydrogels. ( Bajpai, SK; Chand, N; Soni, S, 2015) |
| " Dose-response profile of resveratrol remains indeterminate and additional studies may be necessary to determine effective dosing in diabetes." | 1.42 | Comparison of the anti-diabetic effects of resveratrol, gliclazide and losartan in streptozotocin-induced experimental diabetes. ( Bilgin, HM; Deniz Obay, B; Elbey, B; Şermet, A; Taşdemir, E; Yazgan, ÜC, 2015) |
| "Gliclazide (G) is an antidiabetic drug commonly used in type 2 diabetes." | 1.40 | Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. ( Al-Salami, H; Al-Sallami, HS; Arfuso, F; Chen-Tan, N; Fakhoury, M; Fang, Z; Golocorbin-Kon, S; Mikov, M; Mooranian, A; Mukkur, T; Negrulj, R, 2014) |
| "Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin." | 1.39 | Fisetin averts oxidative stress in pancreatic tissues of streptozotocin-induced diabetic rats. ( Prasath, GS; Subramanian, SP; Sundaram, CS, 2013) |
| " When coadministered with gliclazide, the bioavailability of MKC was reduced in healthy rats treated with probiotics but remained the same in diabetic pretreated rats." | 1.38 | Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. ( Al-Salami, H; Butt, G; Golocorbin-Kon, S; Mikov, M; Tucker, I, 2012) |
| "The threshold of mechanical hyperalgesia was also significantly elevated." | 1.38 | Protective effects of combined therapy of gliclazide with curcumin in experimental diabetic neuropathy in rats. ( Ahmed, AA; Al-Rasheed, NM; Attia, HN; Kenawy, SA; Maklad, YA, 2012) |
| "Approximately 40% of patients with type 2 diabetes may progress to nephropathy and a good metabolic control can prevent the development of diabetic renal injury." | 1.37 | Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats. ( da Cunha, FX; Louro, TM; Matafome, PN; Nunes, EC; Seiça, RM, 2011) |
| " Subsequently, the effects of a 1-week chronic daily dosing of DPP-IV inhibitors and sulfonylureas were investigated." | 1.35 | Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. ( Hayakawa, M; Matsuyama-Yokono, A; Nakano, R; Shibasaki, M; Shiraki, K; Someya, Y; Tahara, A, 2009) |
| "Gliclazide is a second generation of hypoglycemic sulfonylurea and acts selectively on pancreatic beta cell to control diabetes mellitus." | 1.35 | Applying the Taguchi design for optimized formulation of sustained release gliclazide chitosan beads: an in vitro/in vivo study. ( Minayian, M; Rahdari, N; Tavakoli, N; Varshosaz, J, 2009) |
| "The rats with diabetic gastroparesis induced by injecting alloxan and giving 200% Radix Rehmanniae preparata were divided into four groups randomly: Tangweian high dosage group, Tangweian low dosage group, motilium control group and the model control group, 10 rats each group." | 1.35 | [Effects of Tangweian granule on 5-HT(2A)R in rat model with diabetic gastroparesis]. ( Liu, DW; Qian, QH; Qian, WB; Wang, ZC; Zhao, Y, 2008) |
| " Developed Eudragit NPs revealed a decreased t(min) (ELNP), and enhanced bioavailability and sustained activity (ELNP and ERSNP) and hence superior activity as compared to plain gliclazide in streptozotocin induced diabetic rat model and glucose-loaded diabetic rat model." | 1.34 | Preparation and in vitro/in vivo evaluation of gliclazide loaded Eudragit nanoparticles as a sustained release carriers. ( Devarajan, PV; Sonavane, GS, 2007) |
| "Gliclazide is a sulphonylurea antidiabetic drug with anti-oxidant effect due to its azabicyclo-octyl ring." | 1.32 | Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet. ( Fujita, T; Goto, A; Onozato, ML; Tojo, A, 2004) |
| "Gliclazide treatment partly restored these changes (p < 0." | 1.31 | Remodelling of zero-stress state of small intestine in streptozotocin-induced diabetic rats. Effect of gliclazide. ( Gregersen, H; Sha, H; Tong, X; Zhao, J; Zhou, S; Zhuang, FY, 2002) |
| "Gliclazide treatment did not affect the response to acetylcholine of normal rabbit aorta, and gliclazide when added in vitro had no effect on the response of diabetic rabbit aorta, suggesting that the effect of gliclazide was specific to the abnormality arising with diabetes and was not due to an acute effect of the drug." | 1.30 | Vascular action of the hypoglycaemic agent gliclazide in diabetic rabbits. ( Cohen, RA; Griswold, MC; Pagano, PJ; Ravel, D, 1998) |
| "3." | 1.29 | Chronic gliclazide treatment affects basal and post-ischemic cardiac function in diabetic rats. ( Mimura, G; Murakami, K; Nagamine, F; Oshiro, K; Shimabukuro, M, 1994) |
| "2." | 1.29 | Effect of gliclazide on the functional response to calcium in diabetic rat heart. ( Higa, S; Murakami, K; Nagamine, F; Shimabukuro, M; Shinzato, T; Takasu, N, 1996) |
| "Glimepiride is a new sulfonylurea." | 1.29 | Cardiovascular effects of conventional sulfonylureas and glimepiride. ( Geisen, K; Krause, E; Papp, JG; Végh, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (6.19) | 18.7374 |
| 1990's | 16 (16.49) | 18.2507 |
| 2000's | 32 (32.99) | 29.6817 |
| 2010's | 34 (35.05) | 24.3611 |
| 2020's | 9 (9.28) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, A | 3 |
| Pathak, SR | 1 |
| Ahmad, P | 3 |
| Ray, S | 1 |
| Tewari, P | 1 |
| Srivastava, AK | 3 |
| Maurya, RA | 2 |
| Singh, AB | 2 |
| Rathish, IG | 1 |
| Javed, K | 1 |
| Bano, S | 1 |
| Ahmad, S | 1 |
| Alam, MS | 1 |
| Pillai, KK | 1 |
| Sharma, S | 1 |
| Tamrakar, AK | 1 |
| Parvez, M | 1 |
| Hussain, F | 1 |
| Khan, M | 1 |
| El-Kawy, OA | 1 |
| Ibrahim, IT | 1 |
| Shewatah, HA | 1 |
| Attalah, KM | 1 |
| Ungurianu, A | 1 |
| Şeremet, O | 1 |
| Gagniuc, E | 1 |
| Olaru, OT | 1 |
| Guţu, C | 1 |
| Grǎdinaru, D | 1 |
| Ionescu-Tȋrgovişte, C | 1 |
| Marginǎ, D | 1 |
| Dǎnciulescu-Miulescu, R | 1 |
| Panda, BP | 1 |
| Krishnamoorthy, R | 1 |
| Bhattamisra, SK | 1 |
| Shivashekaregowda, NKH | 1 |
| Seng, LB | 1 |
| Patnaik, S | 1 |
| Abdelkader, NF | 1 |
| Eitah, HE | 1 |
| Maklad, YA | 2 |
| Gamaleldin, AA | 1 |
| Badawi, MA | 1 |
| Kenawy, SA | 2 |
| Nazief, AM | 1 |
| Hassaan, PS | 1 |
| Khalifa, HM | 1 |
| Sokar, MS | 1 |
| El-Kamel, AH | 1 |
| Afifi, M | 1 |
| Alkaladi, A | 1 |
| Abomughaid, MM | 1 |
| Abdelazim, AM | 1 |
| Sekar, V | 2 |
| Mani, S | 2 |
| Malarvizhi, R | 2 |
| Barathidasan, R | 1 |
| Vasanthi, HR | 2 |
| Mizar, SMM | 1 |
| Kozman, MR | 1 |
| Abo-Saif, AA | 1 |
| Messiha, BAS | 1 |
| Alkhudhayri, S | 1 |
| Sajini, R | 1 |
| Alharbi, B | 1 |
| Qabbani, J | 1 |
| Al-Hindi, Y | 1 |
| Fairaq, A | 1 |
| Yousef, A | 1 |
| Golocorbin-Kon, S | 4 |
| Calasan, J | 1 |
| Milijasevic, B | 1 |
| Vukmirovic, S | 1 |
| Lalic-Popovic, M | 1 |
| Mikov, M | 5 |
| Al-Salami, H | 7 |
| Zhang, YW | 1 |
| Wang, X | 1 |
| Ren, X | 1 |
| Zhang, M | 1 |
| Danafar, H | 1 |
| Jaberizadeh, H | 1 |
| Andalib, S | 2 |
| Mathavan, S | 2 |
| Chen-Tan, N | 3 |
| Arfuso, F | 4 |
| Yao, H | 1 |
| Feng, J | 1 |
| Zheng, Q | 1 |
| Wei, Y | 1 |
| Yang, G | 1 |
| Feng, W | 1 |
| Nithya, P | 1 |
| Adibkia, K | 1 |
| Babaei, H | 1 |
| Asnaashari, S | 1 |
| Khorrami, A | 1 |
| Ghavimi, H | 1 |
| Jadidinia, V | 1 |
| Hajiloo, H | 1 |
| Barzegar-Jalali, M | 1 |
| Devgan, M | 1 |
| Nanda, A | 1 |
| Ansari, SH | 3 |
| Sharma, VK | 1 |
| Mazumder, B | 1 |
| Mooranian, A | 2 |
| Negrulj, R | 2 |
| Al-Sallami, HS | 2 |
| Fang, Z | 2 |
| Mukkur, T | 1 |
| Fakhoury, M | 2 |
| Aruso, F | 1 |
| Safar, MM | 1 |
| Abdelsalam, RM | 1 |
| Bajpai, SK | 2 |
| Chand, N | 2 |
| Soni, S | 2 |
| Yazgan, ÜC | 1 |
| Taşdemir, E | 1 |
| Bilgin, HM | 1 |
| Deniz Obay, B | 1 |
| Şermet, A | 2 |
| Elbey, B | 1 |
| Ezel, T | 1 |
| Kocyigit, Y | 1 |
| Deveci, E | 1 |
| Atamer, Y | 1 |
| Uysal, E | 1 |
| Aktaş, A | 1 |
| Yavuz, D | 1 |
| Ding, CY | 1 |
| Tan, QY | 1 |
| Shi, NC | 1 |
| Kucheryavenko, AF | 1 |
| Spasov, AA | 1 |
| Anisimova, VA | 1 |
| Mahfoz, AM | 1 |
| El-Latif, HA | 1 |
| Ahmed, LA | 1 |
| Hassanein, NM | 1 |
| Shoka, AA | 1 |
| Tiwari, S | 1 |
| Qian, QH | 1 |
| Wang, ZC | 1 |
| Zhao, Y | 1 |
| Liu, DW | 1 |
| Qian, WB | 1 |
| Butt, G | 2 |
| Tucker, I | 2 |
| Palsamy, P | 2 |
| Subramanian, S | 2 |
| Varshosaz, J | 2 |
| Tavakoli, N | 1 |
| Minayian, M | 1 |
| Rahdari, N | 1 |
| Matsuyama-Yokono, A | 1 |
| Tahara, A | 1 |
| Nakano, R | 1 |
| Someya, Y | 1 |
| Shiraki, K | 1 |
| Hayakawa, M | 1 |
| Shibasaki, M | 1 |
| Gier, B | 1 |
| Krippeit-Drews, P | 1 |
| Sheiko, T | 1 |
| Aguilar-Bryan, L | 1 |
| Bryan, J | 1 |
| Düfer, M | 1 |
| Drews, G | 1 |
| Sivakumar, S | 2 |
| Subramanian, SP | 3 |
| Talari, R | 1 |
| Mostafavi, SA | 1 |
| Nokhodchi, A | 1 |
| Saravanan, G | 2 |
| Ponmurugan, P | 2 |
| Senthil Kumar, GP | 1 |
| Rajarajan, T | 1 |
| Barakat, NS | 2 |
| Almurshedi, AS | 2 |
| Louro, TM | 1 |
| Matafome, PN | 1 |
| Nunes, EC | 1 |
| da Cunha, FX | 1 |
| Seiça, RM | 1 |
| Bhuvaneshwari, S | 1 |
| Prasath, GS | 2 |
| Pal, D | 1 |
| Nayak, AK | 1 |
| Attia, HN | 1 |
| Al-Rasheed, NM | 2 |
| Ahmed, AA | 1 |
| Sun, WP | 1 |
| Bi, Y | 1 |
| Liang, H | 1 |
| Cai, MY | 1 |
| Chen, X | 1 |
| Zhu, YH | 1 |
| Liao, LZ | 1 |
| Weng, JP | 1 |
| Sundaram, CS | 1 |
| Juang, JH | 1 |
| Kuo, CH | 1 |
| Hsu, BR | 1 |
| Zhao, J | 1 |
| Sha, H | 2 |
| Zhou, S | 1 |
| Tong, X | 1 |
| Zhuang, FY | 2 |
| Gregersen, H | 2 |
| Akhtar, MS | 1 |
| Khan, MA | 1 |
| Malik, MT | 1 |
| Jiang, C | 1 |
| Li, Y | 1 |
| Delibas, N | 1 |
| Kilinc, I | 1 |
| Yonden, Z | 1 |
| Sutcu, R | 1 |
| Gultekin, F | 1 |
| Koylu, H | 1 |
| Onozato, ML | 1 |
| Tojo, A | 1 |
| Goto, A | 1 |
| Fujita, T | 1 |
| el-Batran, SA | 1 |
| el-Shenawy, SM | 1 |
| Nofal, SM | 1 |
| Abdel-Salam, OM | 1 |
| Arbid, MS | 1 |
| Mukhtar, HM | 2 |
| Ali, M | 1 |
| Bhat, ZA | 2 |
| Naved, T | 2 |
| Kinukawa, J | 1 |
| Shimura, M | 1 |
| Harata, N | 1 |
| Tamai, M | 1 |
| Alper, G | 1 |
| Irer, S | 1 |
| Duman, E | 1 |
| Caglayan, O | 1 |
| Yilmaz, C | 1 |
| Satyanarayana, S | 1 |
| Sekhar, JR | 1 |
| Kumar, KE | 1 |
| Shannika, LB | 1 |
| Rajanna, B | 1 |
| Rajanna, S | 1 |
| Shan, JJ | 1 |
| Yang, M | 1 |
| Ren, JW | 1 |
| Singh, P | 1 |
| Zhao, JB | 1 |
| Zhang, ZY | 1 |
| Zhou, SP | 1 |
| Tong, XL | 1 |
| Chen, J | 1 |
| Li, WL | 1 |
| Wu, JL | 1 |
| Ren, BR | 1 |
| Zhang, HQ | 1 |
| Devarajan, PV | 1 |
| Sonavane, GS | 1 |
| Al-Kassas, RS | 1 |
| Al-Gohary, OM | 1 |
| Al-Faadhel, MM | 1 |
| Fujitani, B | 2 |
| Maeda, J | 2 |
| Tsuboi, T | 2 |
| Kadokawa, T | 1 |
| Shimizu, M | 2 |
| Ohnota, H | 1 |
| Koizumi, T | 1 |
| Kobayashi, M | 2 |
| Momose, Y | 1 |
| Sato, F | 1 |
| Tormo, MA | 1 |
| Gomez-Zubeldia, MA | 1 |
| Ropero, F | 1 |
| Campillo, JE | 1 |
| Shimabukuro, M | 2 |
| Nagamine, F | 2 |
| Murakami, K | 2 |
| Oshiro, K | 1 |
| Mimura, G | 1 |
| Takahashi, K | 2 |
| Yamatani, K | 1 |
| Hara, M | 1 |
| Sasaki, H | 1 |
| Katsumata, K | 3 |
| Katsumata, Y | 2 |
| Ozawa, T | 1 |
| Shinzato, T | 1 |
| Higa, S | 1 |
| Takasu, N | 1 |
| Takada, Y | 1 |
| Takata, Y | 1 |
| Iwanishi, M | 1 |
| Imamura, T | 1 |
| Sawa, T | 1 |
| Morioka, H | 1 |
| Ishihara, H | 1 |
| Ishiki, M | 1 |
| Usui, I | 1 |
| Temaru, R | 1 |
| Urakaze, M | 1 |
| Satoh, Y | 1 |
| Inami, T | 1 |
| Tsuda, S | 1 |
| Geisen, K | 1 |
| Végh, A | 1 |
| Krause, E | 1 |
| Papp, JG | 1 |
| Pulido, N | 1 |
| Suarez, A | 1 |
| Casanova, B | 1 |
| Romero, R | 1 |
| Rodriguez, E | 1 |
| Rovira, A | 1 |
| Bouskela, E | 1 |
| Cyrino, FZ | 1 |
| Conde, CM | 1 |
| Garcia, AA | 1 |
| Pagano, PJ | 1 |
| Griswold, MC | 1 |
| Ravel, D | 1 |
| Cohen, RA | 1 |
| Qiang, X | 1 |
| Satoh, J | 1 |
| Sagara, M | 1 |
| Fukuzawa, M | 1 |
| Masuda, T | 1 |
| Miyaguchi, S | 1 |
| Toyota, T | 1 |
| Tanira, MO | 1 |
| Furman, BL | 2 |
| Misawa, K | 1 |
| Ichikawa, K | 1 |
| Ojima, K | 1 |
| Hamano, S | 1 |
| Kitamura, T | 1 |
| Komatsu, H | 1 |
| Okuda, Y | 1 |
| Kobayashi, K | 1 |
| Ohmori, H | 1 |
| Sone, H | 1 |
| Suzuki, M | 2 |
| Ma, J | 1 |
| Nakajima, T | 1 |
| Yamada, N | 1 |
| Yamashita, K | 2 |
| Suzuki, S | 2 |
| Kinoshita, N | 1 |
| Kakehashi, A | 1 |
| Inoda, S | 1 |
| Itou, Y | 1 |
| Kuroki, M | 1 |
| Yasu, T | 1 |
| Kawakami, M | 1 |
| Kanazawa, Y | 1 |
| Musbah, MO | 1 |
| Kuwashima, J | 1 |
| Komiya, M | 1 |
| Nakamura, K | 1 |
| Kaneko, H | 1 |
| Yoshida, K | 1 |
| Kojima, K | 1 |
| Harada, T | 1 |
| Awaya, S | 1 |
| Ichikawa, H | 1 |
| Portha, B | 2 |
| Serradas, P | 2 |
| Kawai, K | 1 |
| Murayama, Y | 1 |
| Watanabe, Y | 1 |
| Bailbé, D | 1 |
| Lesobre, B | 1 |
1 review available for gliclazide and Alloxan Diabetes
| Article | Year |
|---|---|
[Physiopathology of non-insulin-dependent diabetes. New therapeutic approaches with gliclazide].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; In | 1988 |
96 other studies available for gliclazide and Alloxan Diabetes
| Article | Year |
|---|---|
Novel substituted naphthalen-1-yl-methanone derivatives as anti-hyperglycemic agents.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Naphthalenes; Ra | 2006 |
Novel 2-aryl-naphtho[1,2-d]oxazole derivatives as potential PTP-1B inhibitors showing antihyperglycemic activities.
Topics: Animals; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Hypoglycemic Agents; Lipids; Mice; Oxaz | 2009 |
Synthesis and blood glucose lowering effect of novel pyridazinone substituted benzenesulfonylurea derivatives.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relat | 2009 |
Design and synthesis of 3,5-diarylisoxazole derivatives as novel class of anti-hyperglycemic and lipid lowering agents.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dos | 2009 |
Crude extract from
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Euphorbia; Gliclazide; Glyburide; | 2023 |
Preparation and evaluation of radiolabeled gliclazide parenteral nanoemulsion as a new tracer for pancreatic β-cells mass.
Topics: Animals; Diabetes Mellitus, Experimental; Emulsions; Gliclazide; Insulin-Secreting Cells; Iodine Rad | 2023 |
Preclinical and clinical results regarding the effects of a plant-based antidiabetic formulation versus well established antidiabetic molecules.
Topics: Aged; Animals; Blood Glucose; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fem | 2019 |
Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model.
Topics: Animals; Biological Availability; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Diab | 2019 |
New combination therapy of gliclazide and quercetin for protection against STZ-induced diabetic rats.
Topics: Animals; Blood Glucose; C-Peptide; Cholesterol; Diabetes Mellitus, Experimental; Drug Therapy, Combi | 2020 |
Lipid-Based Gliclazide Nanoparticles for Treatment of Diabetes: Formulation, Pharmacokinetics, Pharmacodynamics and Subacute Toxicity Study.
Topics: Administration, Oral; Animals; Biological Availability; Diabetes Mellitus, Experimental; Drug Libera | 2020 |
Nanocurcumin improved glucose metabolism in streptozotocin-induced diabetic rats: a comparison study with Gliclazide.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Gliclazide; Glucose; Liver; Male; Rats; Rat | 2020 |
Positive interaction of mangiferin with selected oral hypoglycemic drugs: a therapeutic strategy to alleviate diabetic nephropathy in experimental rats.
Topics: Animals; Antioxidants; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Nephropathies; D | 2020 |
Combination of Captopril with Gliclazide Decreases Vascular and Renal Complications and Improves Glycemic Control in Rats with Streptozotocin- Induced Diabetes Mellitus.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Aorta, Thoracic; Blood Glucose; Blo | 2021 |
Investigating the beneficial effect of aliskiren in attenuating neuropathic pain in diabetic Sprague-Dawley rats.
Topics: Amides; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Progression; Drug T | 2021 |
High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect.
Topics: Animals; Bile Acids and Salts; Blood Glucose; Cholic Acid; Diabetes Mellitus, Experimental; Diabetes | 2017 |
Involvement of glucose-regulated protein 78 and spliced X-box binding protein 1 in the protective effect of gliclazide in diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Gliclazide | 2018 |
In vitro and in vivo delivery of gliclazide loaded mPEG-PCL micelles and its kinetic release and solubility study.
Topics: Animals; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Gliclazide; Male; Micelles; R | 2018 |
Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid.
Topics: Administration, Oral; Animals; Bile Acids and Salts; Capsules; Cell Line; Cell Survival; Diabetes Me | 2018 |
Comparison of the Effects of Prophylactic and Therapeutic Administrations on Peripheral Neuropathy in Streptozotocin-Diabetic Rats with Gliclazide or Methylcobalamin.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Gliclazide; Hypoglycemic Agents; Ra | 2020 |
Antidiabetic effect of mangiferin in combination with oral hypoglycemic agents metformin and gliclazide.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Enzymes; | 2019 |
Serum concentrations and hypoglycemic effect of gliclazide: crosspovidone solid dispersion on streptozotocin induced diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Carriers; Gliclazide; Hypoglycemic Age | 2013 |
Comparative evaluation of the anti-diabetic activity of Pterocarpus marsupium Roxb. heartwood in alloxan induced diabetic rats using extracts obtained by optimized conventional and non conventional extraction methods.
Topics: Alloxan; Animals; Biomarkers; Blood Glucose; Chemical Fractionation; Diabetes Mellitus, Experimental | 2013 |
Gastrointestinal transition and anti-diabetic effect of Isabgol husk microparticles containing gliclazide.
Topics: Alginates; Animals; Blood Glucose; Chemistry, Pharmaceutical; Delayed-Action Preparations; Diabetes | 2014 |
Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study.
Topics: Alginates; Animals; Artificial Cells; Capsules; Chemistry, Pharmaceutical; Deoxycholic Acid; Diabete | 2014 |
Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment.
Topics: Alginates; Animals; Capsules; Deoxycholic Acid; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2015 |
H2S donors attenuate diabetic nephropathy in rats: Modulation of oxidant status and polyol pathway.
Topics: Aldehyde Reductase; Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; | 2015 |
Controlled release of anti-diabetic drug Gliclazide from poly(caprolactone)/poly(acrylic acid) hydrogels.
Topics: Acetone; Acrylamides; Acrylates; Acrylic Resins; Animals; Caproates; Delayed-Action Preparations; Di | 2015 |
Comparison of the anti-diabetic effects of resveratrol, gliclazide and losartan in streptozotocin-induced experimental diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Gliclazide; Glycated Hemoglobin; Hypoglycem | 2015 |
Biochemical and Histopathological Investigation of Resveratrol, Gliclazide, and Losartan Protective Effects on Renal Damage in a Diabetic Rat Model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Diabetes Mellitus, Experimental; Dia | 2015 |
[Alisma versus Gliclazide in the Treatment of Primary Diabetes in Goto-Kakizaki Rats].
Topics: Alisma; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Gliclazide; Rats; Rats | 2015 |
A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes.
Topics: Alginates; Animals; Bile Acids and Salts; Blood Glucose; Capsules; Cell Survival; Diabetes Mellitus, | 2016 |
Effect of a New Antioxidant Enoxifol on Platelet Aggregation and Blood Rheological Properties in Rats with Experimental Diabetes Mellitus.
Topics: Animals; Animals, Outbred Strains; Antioxidants; Benzimidazoles; Blood Glucose; Blood Viscosity; Dia | 2016 |
Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats.
Topics: Amides; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; B | 2016 |
Swelling behavior of cross-linked dextran hydrogels and preliminary Gliclazide release behavior.
Topics: Animals; Delayed-Action Preparations; Dextrans; Diabetes Mellitus, Experimental; Drug Carriers; Drug | 2016 |
[Effects of Tangweian granule on 5-HT(2A)R in rat model with diabetic gastroparesis].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Drugs, Chinese Herb | 2008 |
Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics.
Topics: Alloxan; Animals; ATP-Binding Cassette Transporters; Bile Acids and Salts; Chenodeoxycholic Acid; Di | 2008 |
Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats.
Topics: Administration, Oral; Animals; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Disease Mod | 2009 |
Applying the Taguchi design for optimized formulation of sustained release gliclazide chitosan beads: an in vitro/in vivo study.
Topics: Animals; Blood Glucose; Chemistry, Pharmaceutical; Chitosan; Cross-Linking Reagents; Delayed-Action | 2009 |
Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Pepti | 2009 |
Suppression of KATP channel activity protects murine pancreatic beta cells against oxidative stress.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Blood Glucose; Calcium; Diabetes Mellitus, Experime | 2009 |
D-pinitol attenuates the impaired activities of hepatic key enzymes in carbohydrate metabolism of streptozotocin-induced diabetic rats.
Topics: Animals; Body Weight; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Gliclazide; Glucose | 2009 |
Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats.
Topics: Animals; Antioxidants; Cytokines; Diabetes Mellitus, Experimental; Gliclazide; Hepatocytes; Hypergly | 2010 |
Gliclazide microcrystals prepared by two methods of in situ micronization: pharmacokinetic studies in diabetic and normal rats.
Topics: Administration, Oral; Animals; Crystallization; Diabetes Mellitus, Experimental; Drug Compounding; G | 2010 |
Antidiabetic effect of S-allylcysteine: Effect on plasma and tissue glycoproteins in experimental diabetes.
Topics: Animals; Blood; Blood Glucose; Cysteine; Diabetes Mellitus, Experimental; Garlic; Gliclazide; Glycop | 2010 |
Beneficial effect of S-allylcysteine (SAC) on blood glucose and pancreatic antioxidant system in streptozotocin diabetic rats.
Topics: Animals; Antioxidants; Blood Glucose; Cysteine; Diabetes Mellitus, Experimental; Garlic; Gliclazide; | 2010 |
Design and development of gliclazide-loaded chitosan for oral sustained drug delivery: in vitro/in vivo evaluation.
Topics: Administration, Oral; Animals; Chitosan; Diabetes Mellitus, Experimental; Drug Delivery Systems; Gli | 2011 |
Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dia | 2011 |
Design and development of gliclazide-loaded chitosan microparticles for oral sustained drug delivery: in-vitro/in-vivo evaluation.
Topics: Administration, Oral; Animals; Blood Glucose; Calorimetry, Differential Scanning; Chitosan; Cross-Li | 2011 |
Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.
Topics: Administration, Oral; Animals; Biological Availability; Blood Glucose; Chenodeoxycholic Acid; Cholic | 2012 |
Antidiabetic and antioxidant potentials of Euphorbia hirta leaves extract studied in streptozotocin-induced experimental diabetes in rats.
Topics: Administration, Oral; Animals; Antioxidants; Diabetes Mellitus, Experimental; Euphorbia; Gliclazide; | 2011 |
Development, optimization, and anti-diabetic activity of gliclazide-loaded alginate-methyl cellulose mucoadhesive microcapsules.
Topics: Adhesiveness; Administration, Oral; Alginates; Animals; Blood Glucose; Calcium Chloride; Capsules; C | 2011 |
Protective effects of combined therapy of gliclazide with curcumin in experimental diabetic neuropathy in rats.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Peptide; Curc | 2012 |
[The effects of insulin and gliclazide therapy on endoplasmic reticulum stress and insulin sensitivity in liver of type 2 diabetic rats].
Topics: Animals; Diabetes Mellitus, Experimental; Endoplasmic Reticulum Stress; Gliclazide; Insulin; Insulin | 2012 |
Fisetin averts oxidative stress in pancreatic tissues of streptozotocin-induced diabetic rats.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Drug Evaluation, Preclinical; | 2013 |
Effect of gliclazide on islet transplants.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Gliclazide; Hypoglycemic Agent | 2002 |
Remodelling of zero-stress state of small intestine in streptozotocin-induced diabetic rats. Effect of gliclazide.
Topics: Animals; Diabetes Mellitus, Experimental; Gliclazide; Hypoglycemic Agents; Intestine, Small; Male; R | 2002 |
Hypoglycaemic activity of Alpinia galanga rhizome and its extracts in rabbits.
Topics: Alloxan; Alpinia; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dose-Response Relationshi | 2002 |
[Effects of gliclazide on blood rheology of diabetes Wistar rat].
Topics: Animals; Blood Viscosity; Diabetes Mellitus, Experimental; Female; Gliclazide; Hemorheology; Hypogly | 2001 |
NMDA receptor subunits 2A and 2B decrease and lipid peroxidation increase in the hippocampus of streptozotocin-diabetic rats: effects of insulin and gliclazide treatments.
Topics: Animals; Blotting, Western; Diabetes Mellitus, Experimental; Gliclazide; Hippocampus; Hypoglycemic A | 2004 |
Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet.
Topics: Animals; Blood Pressure; Cholesterol, Dietary; Diabetes Mellitus, Experimental; Diabetic Nephropathi | 2004 |
Studies on the glycemic and lipidemic effect of monopril and losartan in normal and diabetic rats.
Topics: Alloxan; Animals; Blood Glucose; Blood Proteins; Carbamates; Cholesterol, LDL; Diabetes Mellitus, Ex | 2004 |
[2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug | 2004 |
Effect of aqueous extract of Cyamopsis tetragonoloba Linn. beans on blood glucose level in normal and alloxan-induced diabetic rats.
Topics: Animals; Blood Glucose; Cyamopsis; Diabetes Mellitus, Experimental; Female; Gliclazide; Hypoglycemic | 2004 |
Gliclazide attenuates the intracellular Ca2+ changes induced in vitro by ischemia in the retinal slices of rats with streptozotocin-induced diabetes.
Topics: Aniline Compounds; Animals; Calcium; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Gliclazi | 2005 |
Effect of I-deprenyl and gliclazide on oxidant stress/antioxidant status and dna damage in a diabetic rat model.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aging; Animals; Antioxidants; Blood Glucose; Body Weight; Deoxyguanosin | 2005 |
Influence of selenium (antioxidant) on gliclazide induced hypoglycaemia/anti hyperglycaemia in normal/alloxan-induced diabetic rats.
Topics: Administration, Oral; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Drug Th | 2006 |
Anti-diabetic and hypolipidemic effects of aqueous-extract from the flower of Inula japonica in alloxan-induced diabetic mice.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Drinking; Eating; Flowers; Gli | 2006 |
Antidiabetic activity of an ethanol extract obtained from the stem bark of Psidium guajava (Myrtaceae).
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Ethanol; Female; Gliclazide; Glucose Tolera | 2006 |
Effect of Kaiyu Qingwei Jianji on the morphometry and residual strain distribution of small intestine in experimental diabetic rats.
Topics: Animals; Biomechanical Phenomena; Biometry; Blood Glucose; Diabetes Mellitus, Experimental; Gliclazi | 2006 |
Hypoglycemic effects of a sesquiterpene glycoside isolated from leaves of loquat (Eriobotrya japonica (Thunb.) Lindl.).
Topics: Administration, Oral; Alloxan; Animals; Blood Glucose; Carbohydrate Sequence; Diabetes Mellitus, Exp | 2008 |
Preparation and in vitro/in vivo evaluation of gliclazide loaded Eudragit nanoparticles as a sustained release carriers.
Topics: Administration, Oral; Animals; Biological Availability; Blood Glucose; Cetrimonium; Cetrimonium Comp | 2007 |
Controlling of systemic absorption of gliclazide through incorporation into alginate beads.
Topics: Administration, Oral; Alginates; Animals; Blood Glucose; Chemistry, Pharmaceutical; Delayed-Action P | 2007 |
Effect of gliclazide on prostaglandin I2 formation in normal and streptozotocin-induced diabetic animals.
Topics: Animals; Aorta; Blood Glucose; Blood Platelets; Blood Vessels; Diabetes Mellitus, Experimental; Epop | 1983 |
Normalization of impaired glucose tolerance by the short-acting hypoglycemic agent calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate (KAD-1229) in non-insulin-dependent diabetes mellitus rats.
Topics: Animals; Animals, Newborn; Blood Glucose; Diabetes Mellitus, Experimental; Food; Gliclazide; Glucose | 1995 |
Effect of insulin and gliclazide on glucose utilization by a perfused intestine-pancreas preparation isolated from diabetic and non-diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Gliclazide; Glucose; In Vitro Techniques; I | 1994 |
Chronic gliclazide treatment affects basal and post-ischemic cardiac function in diabetic rats.
Topics: Adenosine Triphosphate; Animals; Diabetes Mellitus, Experimental; Gliclazide; Heart; Lactates; Lacti | 1994 |
Gliclazide directly suppresses arginine-induced glucagon secretion.
Topics: Animals; Arginine; Cysteamine; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Dr | 1994 |
Potentiating effects of combined usage of three sulfonylurea drugs on the occurrence of alloxan diabetes in rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Combinations; Drug Synergism; Gliclazi | 1993 |
Effect of gliclazide on the functional response to calcium in diabetic rat heart.
Topics: Animals; Blood Glucose; Blood Pressure; Calcium; Diabetes Mellitus, Experimental; Gliclazide; Glycat | 1996 |
Effect of glimepiride (HOE 490) on insulin receptors of skeletal muscles from genetically diabetic KK-Ay mouse.
Topics: Animals; Diabetes Mellitus, Experimental; Diglycerides; Gliclazide; Hypoglycemic Agents; Insulin; Ma | 1996 |
Cardiovascular effects of conventional sulfonylureas and glimepiride.
Topics: Animals; Blood Pressure; Cardiovascular System; Coronary Vessels; Diabetes Mellitus, Experimental; D | 1996 |
Gliclazide treatment of streptozotocin diabetic rats restores GLUT4 protein content and basal glucose uptake in skeletal muscle.
Topics: Animals; Diabetes Mellitus, Experimental; Gliclazide; Glucose; Glucose Transporter Type 4; Hindlimb; | 1997 |
Microvascular permeability with sulfonylureas in normal and diabetic hamsters.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Capillary Permeability; Cricetinae; Dextrans; D | 1997 |
Vascular action of the hypoglycaemic agent gliclazide in diabetic rabbits.
Topics: Acetylcholine; Animals; Aorta, Abdominal; Blood Glucose; Diabetes Mellitus, Experimental; Endotheliu | 1998 |
Gliclazide inhibits diabetic neuropathy irrespective of blood glucose levels in streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Gliclaz | 1998 |
The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Drug Interactions; Fatty Acids, | 1999 |
Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs.
Topics: Animals; Anti-Bacterial Agents; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Anim | 2001 |
Acute gliclazide administration enhances glucose and ketone body utilization in the perfused hind limb of normal and streptozotocin-diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Fasting; Gliclazide; Glucose; Hindlimb; Hyp | 2002 |
Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide.
Topics: Animals; Cell Adhesion; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Gliclazide; Hypoglyce | 2002 |
Studies on the hypoglycaemic action of gliclazide, a sulphonyl-urea drug [proceedings].
Topics: Animals; Diabetes Mellitus, Experimental; Fatty Acids, Nonesterified; Gliclazide; Hypoglycemic Agent | 1977 |
[Inhibitory effect of gliclazide on platelet adhesiveness and aggregation in alloxan diabetic rabbits (author's transl)].
Topics: Animals; Depression, Chemical; Diabetes Mellitus, Experimental; Gliclazide; Male; Platelet Adhesiven | 1979 |
[The adhesiveness of platelets and the alteration of retinal capillaries. An experimental study in streptozotocin-induced diabetic rats (author's transl)].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Gliclazide; Platelet Adhesiveness; R | 1979 |
Improvement in glucose-induced insulin secretion in diabetic rats after long-term gliclazide treatment: a comparative study using different models of non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gliclazide; Insu | 1991 |
Comparison of beta-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats.
Topics: Animals; Animals, Newborn; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mel | 1991 |
The potentiating effect of the simultaneous administration of tolbutamide, glibenclamide, and gliclazide on the development of alloxan-induced diabetes in rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Synergism; Gliclazide; Gl | 1990 |
Long-term gliclazide treatment improves the in vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin.
Topics: Animals; Animals, Newborn; Arginine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellit | 1989 |